DE
FR
IT
ES
A new generation of hormone therapy for breast cancer
The use of hormonal drugs in the case of a carcinogenic process of the mammary gland is one of the fundamental types of therapeutic approach. Direct determination of a particular medication, depending on the goals of treatment:
- Neoadjuvant therapy - it is prescribed before surgery when the size of the neoplasm is not more than 2 cm with the involvement of the lymph nodes in the pathological process.
- Conservative - indicated in the presence of an inoperable process to reduce tumor foci.
- Adjuvant treatment - used as a prophylaxis after taking other cancer drugs to minimize the possibility of recurrence.
Currently, oncologists in each of these types of treatment use the drug Arimidex, which is an anticancer non-steroidal aromatase inhibitor with a highly selective ability.
The main effect of the drug is to suppress the formation of estrogen hormones. Due to the fact that in the blood of women there is a decrease in the circulating estradiol in the blood, an antitumor effect is realized during treatment. Such an action of the drug is an indication for buying Arimidex for the treatment of malignant lesions of the mammary gland of various types and in different age periods of women.
Arimidex for neoadjuvant treatment of breast cancer
With locally advanced breast cancer in women in whom the pathology is detected for the first time and is subject to surgery, the leading standard therapeutic tactic is the appointment of Arimidex. The prevailing goal of such a treated approach is to perform an operative intervention that can preserve the organ.
Thanks to the implementation of treatment courses with the use of Arimidex, it is possible to reduce the frequency of surgical operations for the removal of the mammary glands, as well as the frequency of relapses of the oncological malignant process.
This treatment is most effective in postmenopausal women with a hormone-dependent tumor who needed a mastectomy operation with no indication for chemotherapy.
Arimidex for metastatic breast cancer
![blockquote]()
With this form of malignant formation, the main goal of therapy is to maximize the therapeutic effect, increase the life expectancy of patients, as well as its quality.
The advantages of the drug Arimidex in these cases are due to the small number of side effects, the absence of complications in the form of thromboembolism and the development of proliferative processes in the endometrium.
In addition, since the drug does not significantly affect the synthesis of aldosterone and cortisol, women are not prescribed additional hormone replacement therapy. This makes it possible to reduce the drug load on the body and the overall cost of the therapy.
Moreover, if there is no effect against the background of the anti-tumor therapy with tamoxifen or the deterioration in this condition of patients due to the progression of cancer, Arimidex becomes the first-line drug.
Overall, the initiation of the use of Arimidex in postmenopausal women with hormone-sensitive tumors has significantly expanded treatment success. In the later stages, the drug allows to achieve stabilization of the patient's condition. In the case of an early pathological process, they can increase the survival of patients without cancer recurrence, and in patients with a poor prognosis, they can improve overall survival rates.
The delay in starting therapy for the malignant process is currently associated with the fact that it is practically impossible to buy Arimidex at the pharmacy. The considerable number of pharmacies that have the drug in stock, the prices for it are quite high. This does not allow all women to receive high-quality and effective treatment for their disease.
